Decompensated Heart Failure
Conditions
Keywords
Decompensated heart failure
Brief summary
Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year. Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2). Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality. The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.
Interventions
OTHERHospitalized patient for decompensated heart failure
Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient ≥ 18 years * Hospitalized (≥24h) for decompensated heart failure in cardiology.
Exclusion criteria
* Patient opposition participation in research and use of data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prescription score | During hospitalisation for decompensated heart failure (up to 10 days) | Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum concentration of creatinine | During hospitalisation for decompensated heart failure (up to10 days) | Creatinine measured at admission and discharge |
| serum concentration of potassium | During hospitalisation for decompensated heart failure (up to 10 days) | Potassium measured at admission and discharge |
| Concentration of hemoglobin | During hospitalisation for decompensated heart failure (up to 10 days) | hemoglobin measured at admission and discharge |
| All cause Death | 6 months | — |
| Rate of hospitalization for heart failure | 6 months | — |
Countries
France
Contacts
STUDY_CHAIRNicolas GIRERD, MD-PhD
CHRU de NANCY
Outcome results
None listed